Form 13-F position report

GENERATION BIO CO

Reported by MORGAN STANLEY

GBIO CUSIP 37148K100 Manager CIK 0000895421

Reported 213,264 shares, down 30,802 (12.6%) from the prior quarter.

Reported value -9.4%; share count -12.6% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q1 2022
Shares 213,264 Quarter-end amount reported
Reported value $1,565,000 Fair value at quarter end
Consecutive quarters held 7 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 1727000
2022-03-31 1565000
2022-06-30 1334000
2022-09-30 2584000
2022-12-31 1933464
2023-03-31 2209314
2023-06-30 2883222
2023-09-30 1906257
2023-12-31 1755705
2024-03-31 3833054
2024-06-30 2640637
2024-09-30 2469188
2024-12-31 996217
2025-03-31 355970
2025-06-30 292198
2025-09-30 0
2025-09-30 1005333
2025-12-31 916627
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for GENERATION BIO CO held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -161,378 (-100.0%) 0 $0 2026-05-15
Q4 2025 Reduced 161,378 -2,892 (-1.8%) < 0.01% $916,627 2026-02-13
Q3 2025 New 164,270 +164,270 (0.0%) < 0.01% $1,005,333 2025-11-14
Q3 2025 Reduced 0 -912,834 (-100.0%) 0 $0 2025-11-14
Q2 2025 Added 912,834 +33,898 (3.9%) < 0.01% $292,198 2025-08-15
Q1 2025 Reduced 878,936 -60,891 (-6.5%) < 0.01% $355,970 2025-05-15
Q4 2024 Reduced 939,827 -59,844 (-6.0%) < 0.01% $996,217 2025-02-14
Q3 2024 Added 999,671 +63,275 (6.8%) < 0.01% $2,469,188 2024-11-14
Q2 2024 Reduced 936,396 -5,386 (-0.6%) < 0.01% $2,640,637 2024-08-14
Q1 2024 Reduced 941,782 -122,282 (-11.5%) < 0.01% $3,833,054 2024-05-15
Q4 2023 Added 1,064,064 +561,094 (111.6%) < 0.01% $1,755,705 2024-02-13
Q3 2023 Reduced 502,970 -21,252 (-4.1%) < 0.01% $1,906,257 2023-11-15
Q2 2023 Added 524,222 +10,428 (2.0%) < 0.01% $2,883,222 2023-08-14
Q1 2023 Added 513,794 +21,818 (4.4%) < 0.01% $2,209,314 2023-05-15
Q4 2022 Added 491,976 +5,210 (1.1%) < 0.01% $1,933,464 2023-02-14
Q3 2022 Added 486,766 +283,337 (139.3%) < 0.01% $2,584,000 2022-11-14
Q2 2022 Reduced 203,429 -9,835 (-4.6%) < 0.01% $1,334,000 2022-08-15
Q1 2022 Reduced 213,264 -30,802 (-12.6%) < 0.01% $1,565,000 2022-05-13
Q4 2021 Added 244,066 +7,270 (3.1%) < 0.01% $1,727,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

103 managers reported GENERATION BIO CO for Q1 2022.

Managers reporting GENERATION BIO CO in Q1 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PRICE T ROWE ASSOCIATES INC MD Added 8,763,691 +116,570 < 0.01% $64,325,000 8 qtrs
FMR LLC Added 8,550,767 +14,305 < 0.01% $62,762,631 8 qtrs
Atlas Venture Life Science Advisors LLC Unchanged 8,278,876 0 7.68% $60,767,000 2 qtrs
Bellevue Group AG Reduced 3,682,180 -190,000 0.31% $27,027,000 8 qtrs
VANGUARD GROUP INC Reduced 3,549,177 -45,284 < 0.01% $26,051,000 8 qtrs
FARALLON CAPITAL MANAGEMENT LLC Unchanged 3,500,000 0 0.12% $25,690,000 8 qtrs
BlackRock Inc Added 3,168,702 +1,157 < 0.01% $23,260,000 8 qtrs
Artal Group S A Unchanged 2,814,191 0 0.86% $20,656,000 8 qtrs
BVF INC IL Added 2,802,950 +2,613,900 0.82% $20,574,000 2 qtrs
Yiheng Capital Management L P Added 2,597,631 +622,485 0.87% $19,067,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 13, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
211,904
Shared
868
None
492

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.